

Argentina

Tuberculosis profile

Population 2013

41 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.57 (0.54–0.59)	1.4 (1.3–1.4)
Mortality (HIV+TB only)	0.044 (0.012–0.096)	0.11 (0.03–0.23)
Prevalence (includes HIV+TB)	13 (5.6–23)	31 (14–56)
Incidence (includes HIV+TB)	10 (9.1–12)	24 (22–28)
Incidence (HIV+TB only)	0.27 (0.25–0.61)	0.65 (0.61–1.5)
Case detection, all forms (%)	89 (78–98)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	2.2 (1.2–3.6)	15 (9.8–23)
MDR-TB cases among notified pulmonary TB cases	160 (87–260)	200 (130–300)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	5 223	357
Pulmonary, clinically diagnosed	2 054	74
Extrapulmonary	1 188	37

Total new and relapse	8 933
Previously treated, excluding relapses	881
Total cases notified	9 814

Among 8 933 new and relapse cases:

893 (10%) cases aged under 15 years; male:female ratio: 1.4

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	1 429 (27%)	728 (54%)	3 157
Laboratory-confirmed RR-/MDR-TB cases			85
Patients started on MDR-TB treatment			

TB/HIV 2013	Number	(%)
TB patients with known HIV status	1 720	(18)
HIV-positive TB patients	775	(45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	56
Previously treated cases, excluding relapse, registered in 2012	44
HIV-positive TB cases, all types, registered in 2012	24
RR-/MDR-TB cases started on second-line treatment in 2011	28
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	1.7
Culture (per 5 million population)	18.2
Drug susceptibility testing (per 5 million population)	2.1
Sites performing Xpert MTB/RIF	0
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	2.4
% Funded domestically	100%
% Funded internationally	0%
% Unfunded	0%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded